FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3090217457> ?p ?o ?g. }

• W3090217457 endingPage "6157" @default.
• W3090217457 startingPage "6149" @default.
• W3090217457 abstract "To determine whether the androgen receptor (AR) inhibitor, enzalutamide, improves effectiveness of endocrine therapy (ET) in hormone receptor-positive (HR+) breast cancer.In this phase II trial, patients with HR+/HER2 normal advanced/metastatic breast cancer were randomized 1:1 to exemestane 25 mg with placebo or exemestane 50 mg with enzalutamide 160 mg daily (NCT02007512). Two parallel cohorts enrolled patients with 0 (cohort 1) or 1 (cohort 2) prior ET for advanced disease. Progression-free survival (PFS) was the primary endpoint in the intent-to-treat (ITT) population of each cohort. Biomarkers were evaluated in an exploratory analysis.Overall, 247 patients were randomized (cohort 1, n = 127 and cohort 2, n = 120). PFS was not improved in either cohort of the ITT population [HR, 0.82 (95% confidence interval (CI), 0.54-1.26); P = 0.3631 for cohort 1 and HR, 1.02 (95% CI, 0.66-1.59); P = 0.9212 for cohort 2]. In cohort 1, high levels of AR mRNA were associated with greater benefit of enzalutamide (Pinteraction = 0.0048). This effect was particularly apparent in patients with both high levels of AR mRNA and low levels of ESR1 mRNA [HR, 0.24 (95% CI, 0.10-0.60); P = 0.0011]. The most common any grade adverse events in the enzalutamide arms were nausea (39%) in cohort 1 and fatigue (37%) in cohort 2.Enzalutamide with exemestane was well tolerated. While PFS was not improved by the addition of enzalutamide to exemestane in an unselected population, ET-naïve patients with high AR mRNA levels, particularly in combination with low ESR1 mRNA levels, may benefit from enzalutamide with exemestane." @default.
• W3090217457 created "2020-10-08" @default.
• W3090217457 creator A5010064853 @default.
• W3090217457 creator A5013955755 @default.
• W3090217457 creator A5018118709 @default.
• W3090217457 creator A5019041034 @default.
• W3090217457 creator A5021039094 @default.
• W3090217457 creator A5022422153 @default.
• W3090217457 creator A5023548391 @default.
• W3090217457 creator A5030497065 @default.
• W3090217457 creator A5031423623 @default.
• W3090217457 creator A5031499770 @default.
• W3090217457 creator A5032785430 @default.
• W3090217457 creator A5037491015 @default.
• W3090217457 creator A5047113165 @default.
• W3090217457 creator A5050421775 @default.
• W3090217457 creator A5053376791 @default.
• W3090217457 creator A5067642403 @default.
• W3090217457 creator A5070245248 @default.
• W3090217457 creator A5072563567 @default.
• W3090217457 creator A5075425924 @default.
• W3090217457 creator A5075889627 @default.
• W3090217457 creator A5076556096 @default.
• W3090217457 creator A5077097017 @default.
• W3090217457 creator A5084565053 @default.
• W3090217457 creator A5089226137 @default.
• W3090217457 date "2020-12-01" @default.
• W3090217457 modified "2023-10-10" @default.
• W3090217457 title "A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor–Positive Breast Cancer" @default.
• W3090217457 cites W1969154275 @default.
• W3090217457 cites W2013147142 @default.
• W3090217457 cites W2035921832 @default.
• W3090217457 cites W2074619468 @default.
• W3090217457 cites W2107617686 @default.
• W3090217457 cites W2136879321 @default.
• W3090217457 cites W2148643283 @default.
• W3090217457 cites W2166918329 @default.
• W3090217457 cites W2171034209 @default.
• W3090217457 cites W2213568616 @default.
• W3090217457 cites W2471690942 @default.
• W3090217457 cites W2510574450 @default.
• W3090217457 cites W2591021490 @default.
• W3090217457 cites W2593628479 @default.
• W3090217457 cites W2603390198 @default.
• W3090217457 cites W2729192524 @default.
• W3090217457 cites W2784775153 @default.
• W3090217457 cites W2790461643 @default.
• W3090217457 cites W2810806599 @default.
• W3090217457 cites W2889272013 @default.
• W3090217457 cites W2947893479 @default.
• W3090217457 cites W2963794755 @default.
• W3090217457 cites W3031020438 @default.
• W3090217457 doi "https://doi.org/10.1158/1078-0432.ccr-20-1693" @default.
• W3090217457 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32988969" @default.
• W3090217457 hasPublicationYear "2020" @default.
• W3090217457 type Work @default.
• W3090217457 sameAs 3090217457 @default.
• W3090217457 citedByCount "25" @default.
• W3090217457 countsByYear W30902174572021 @default.
• W3090217457 countsByYear W30902174572022 @default.
• W3090217457 countsByYear W30902174572023 @default.
• W3090217457 crossrefType "journal-article" @default.
• W3090217457 hasAuthorship W3090217457A5010064853 @default.
• W3090217457 hasAuthorship W3090217457A5013955755 @default.
• W3090217457 hasAuthorship W3090217457A5018118709 @default.
• W3090217457 hasAuthorship W3090217457A5019041034 @default.
• W3090217457 hasAuthorship W3090217457A5021039094 @default.
• W3090217457 hasAuthorship W3090217457A5022422153 @default.
• W3090217457 hasAuthorship W3090217457A5023548391 @default.
• W3090217457 hasAuthorship W3090217457A5030497065 @default.
• W3090217457 hasAuthorship W3090217457A5031423623 @default.
• W3090217457 hasAuthorship W3090217457A5031499770 @default.
• W3090217457 hasAuthorship W3090217457A5032785430 @default.
• W3090217457 hasAuthorship W3090217457A5037491015 @default.
• W3090217457 hasAuthorship W3090217457A5047113165 @default.
• W3090217457 hasAuthorship W3090217457A5050421775 @default.
• W3090217457 hasAuthorship W3090217457A5053376791 @default.
• W3090217457 hasAuthorship W3090217457A5067642403 @default.
• W3090217457 hasAuthorship W3090217457A5070245248 @default.
• W3090217457 hasAuthorship W3090217457A5072563567 @default.
• W3090217457 hasAuthorship W3090217457A5075425924 @default.
• W3090217457 hasAuthorship W3090217457A5075889627 @default.
• W3090217457 hasAuthorship W3090217457A5076556096 @default.
• W3090217457 hasAuthorship W3090217457A5077097017 @default.
• W3090217457 hasAuthorship W3090217457A5084565053 @default.
• W3090217457 hasAuthorship W3090217457A5089226137 @default.
• W3090217457 hasBestOaLocation W30902174571 @default.
• W3090217457 hasConcept C121608353 @default.
• W3090217457 hasConcept C126322002 @default.
• W3090217457 hasConcept C142724271 @default.
• W3090217457 hasConcept C143998085 @default.
• W3090217457 hasConcept C168563851 @default.
• W3090217457 hasConcept C197934379 @default.
• W3090217457 hasConcept C203092338 @default.
• W3090217457 hasConcept C204787440 @default.
• W3090217457 hasConcept C27081682 @default.
• W3090217457 hasConcept C2775860665 @default.
• W3090217457 hasConcept C2776166826 @default.

• next